Date: 2015-12-03
Type of information: Grant
Company: EMTherapy consortium (Inventiva (France), 4SC (Germany), Oryzon Genomics (Spain))
Investors: European Eurostars Programme (EU)
Amount: €4.8 million
Funding type: grant
Planned used: The EMTherapy consortium aims to develop epigenetic targets-inhibiting compounds, particularly in oncology, and to build a world-class epigenetics platform in Europe. Inventiva’s role in EMTherapy focuses on NSD2 epigenetic target, which is responsible for oncogenesis in an aggressive form of multiple myeloma. The company has confirmed the role of NSD2 in a human cancer cell model and established its potential as a therapeutic target. Based on the use of its proprietary molecule library, the company has also identified drug-like molecules that are able to inhibit NSD2 activity. These compounds are currently being optimised by Inventiva’s chemistry teams ahead of demonstrating in
vivo proof of concept.
Others: * On December 3, 2015, Inventiva, a biopharmaceutical company specialised in transcription factors and epigenetics for innovative therapies within the fields of fibrosis, oncology and orphan diseases, announced a grant has been obtained by the EMTherapy consortium under the Eurostars program to cover part of the €4.8 million budget. Eurostars supports highly innovative SMEs involved in international collaborative schemes such as EMTherapy’s epigenetics project.
Therapeutic area: Cancer - Oncology
